The Endocrine Society is pleased to offer the Obesity Fellows Program, a blended learning experience on best practices in obesity care, exclusively for endocrinology fellows. Chaired by renowned obesity medicine expert Amy Rothberg, MD, DABOM, and Dimpi Desai, MD, the Obesity Fellows program on September 19-20, 2025, is an exclusive, application-based educational activity for current fellows, offering several modes of learning, including:
- An engaging in-person program located in downtown Washington, D.C., at the Endocrine Society Headquarters, where fellows get the opportunity to meet with the top experts in the field of obesity care and management.
- 6 on-demand lectures with related pre- and post-test questions, covering foundational topics on obesity clinical practice; and
- Complementary Endocrine News podcast episode
The program accepts up to 50 US-domestic fellows for full participation in the in-person program. Travel, 2-night hotel accommodation, and meal expenses will be covered by the Endocrine Society.
The 2025 application period runs April 7 to May 7.
Please contact [email protected] if you have any questions.
2025 Program Agenda
In-Person Workshop:
Friday Evening (September 19):
- Keynote Address: Summarizing the Current State of Obesity Management – Michael Weintraub, MD , New York University Medical Center
- Legislative Update on Treat and Reduce Obesity Act: Why We Need Your Help to Advocate to Congress – Rob Goldsmith, Director of Advocacy and Policy, Endocrine Society
Saturday Morning (September 20):
- Welcome (9:00 – 9:15 AM ET)
- Patient-First Strategies: When & How to Discuss Weight & Factors Affecting Weight Loss and Weight Control (9:15 – 9:50 AM ET)
- NEW - Lifestyle Assessment, Intervention & Monitoring in Obesity (9:55 – 10:30 AM ET)
- NEW - Pediatric Weight Management (10:40 – 11:15 AM ET)
- Updates on Surgical and Procedural Interventions for Obesity (11:20 –11:55 AM ET)
- Lunch (12:00 – 1:00 PM ET)
- Small Group Discussion: Challenging Cases - Managing Polypharmacy & Comorbidities (1:00 – 1:30 PM ET)
- Pharmacologic Treatment for Obesity (New and Old) (1:30 – 2:30 PM ET)
- NEW - Patient perspective (2:40 – 3:15 PM ET)
- Ask the experts (3:20 – 3:55 PM ET)
On-Demand Recordings (on our Center for Learning)
-
Current Prevalence of Obesity and Genetic & Environmental Pathophysiology of Obesity
- Lifestyle Assessment, Intervention & Monitoring in Obesity
- Pharmaceutical Options Pt. 1: Past, Current, and Future Options
- Pharmaceutical Options Pt. 2: FDA-Approved Pharmacotherapeutic Options for the Treatment of Obesity
- Body composition
Learning Objectives:
Upon successful completion these educational initiatives, participants should be better able to:
- Discuss obesity as a multifactorial, chronic, complex disease, strategies for opening dialogues about obesity, and the effect of weight bias on patients.
- Apply updated knowledge of obesity pathophysiology and external environmental factors (e.g. social determinants of health) when developing treatment plans.
- Evaluate the risks, benefits, indications, and recommendations for behavioral counseling, individualized diets, physical activity, and technologies, for weight management.
- Manage the use of FDA-approved anti-obesity medications by integrating short- and long-term efficacy, safety, and patient-specific factors into treatment plans for sustained weight loss.
- Discuss the risks and benefits of weight loss procedures and surgeries and how to incorporate shared-decision making in patient consultations.
This program was supported by an educational grant from Lilly and Novo Nordisk.
Have questions? Please contact [email protected] for assistance.
